A Blueprint for Clinical Trial Transformation: Results from Three Top 20 Biopharmas
Leading biopharma companies are proving that a strategic, data-driven approach to clinical trial management can deliver transformative results across efficiency, innovation, and collaboration. Boehringer Ingelheim consolidated over 40 systems and 70 interfaces into a single clinical platform, while Novo Nordisk is on track to reduce early trial cycle times by 50% and cut study build effort by 20%. Bayer anticipates 15-20% effort savings by eliminating manual trackers and complex data transformations as it expands into cell and gene therapies. Together, these case studies provide a practical blueprint for sponsors seeking to simplify their clinical technology landscape, accelerate time-to-market, and ultimately deliver therapies to patients faster.
In this guide, you'll explore
- Boehringer Ingelheim replaced 40+ systems and 70+ interfaces with a single connected clinical platform, accelerating innovation and enabling near real-time data visibility.
- Novo Nordisk achieved five live trials within 12 months and is targeting a 50% reduction in early trial setup cycle times and a 20% reduction in study build and monitoring effort.
- Bayer anticipates 15-20% effort savings by eliminating manual trackers and complex data transformations, while consolidating over 30 applications and 80 integrations into one platform.
- A machine learning analysis of over 16,000 clinical trials confirms rising trial complexity across all phases over the last decade, reinforcing the urgency for clinical technology transformation.
- Effective change management — including dedicated stakeholder engagement, end-user empowerment, and cross-functional collaboration — was a critical success factor across all three transformation programs.